体外膜氧合期间的急性神经系统并发症:系统评价
该系统评价检索PubMed、Embase和Cochrane数据库,纳入1990至2017年报告成人ECMO期间神经系统并发症的44项队列研究。急性神经系统并发症中位频率13%(1-78%),其中颅内出血5%、缺血性卒中5%、癫痫2%;静脉-动脉ECMO相比静脉-静脉ECMO报告并发症的研究更多(14 vs 8项),静脉-动脉ECMO并发症中位比例15%(6-33%;95%CI 8-19)。合并神经系统并发症者住院死亡中位83%(IQR 54-100%)vs 无并发症者42%(IQR 24-55%),p<0.001;出血、缺血性卒中、癫痫的中位死亡率分别为96%、84%、40%。作者结论认为并发症常见且死亡率高,呼吁每日撤离镇静和神经肌肉阻滞剂以进行神经系统评估并监测凝血,证据质量低至极低。
要点
- 成人ECMO期间急性神经系统并发症中位频率13%(范围1-78%),其中颅内出血5%、缺血性卒中5%、癫痫2%。
- 静脉-动脉ECMO并发症中位比例15%(6-33%;95%CI 8-19),报告并发症的研究数多于静脉-静脉ECMO(14 vs 8项)。
- 合并神经系统并发症者住院死亡中位83%(IQR 54-100%)vs 无并发症者42%(IQR 24-55%),p<0.001;出血死亡率中位96%、缺血性卒中84%、癫痫40%。
- 危险因素包括年龄、ECMO前心脏骤停、低血糖和使用正性肌力药;ECMO前血清乳酸>10 mmol/L与缺血性卒中风险增加相关。
- 作者呼吁每日撤离镇静和神经肌肉阻滞剂以评估神经系统并监测凝血;无研究报告每日凝血监测和神经系统评估,证据质量低至极低。
适用人群与场景
- 成人ECMO患者(1990至2017年队列研究),包括静脉-动脉和静脉-静脉ECMO。
处置流程与药物剂量
- 作者呼吁每日撤离镇静和神经肌肉阻滞剂以进行神经系统评估,并监测凝血。
研究设计与关键结果
- 系统评价纳入44项队列研究,成人ECMO期间急性神经系统并发症中位频率13%(1-78%),颅内出血5%、缺血性卒中5%、癫痫2%。
- 静脉-动脉ECMO并发症中位比例15%(6-33%;95%CI 8-19),报告并发症的研究数多于静脉-静脉ECMO(14 vs 8项)。
- 合并神经系统并发症者住院死亡中位83%(IQR 54-100%)vs 无并发症者42%(IQR 24-55%),p<0.001;出血中位死亡率96%、缺血性卒中84%、癫痫40%。
- 危险因素包括年龄、ECMO前心脏骤停、低血糖和正性肌力药使用;出血与女性、通气及ECMO持续时间、血清纤维蛋白原降低、肝素、血清肌酐>2.6 mg/dL、血液透析和血小板减少相关;ECMO前血清乳酸>10 mmol/L与缺血性卒中风险增加相关。
- 无研究报告每日凝血监测和神经系统评估,证据质量低至极低。
证据类型、等级与局限
- 证据类型:系统评价,纳入1990至2017年44项队列研究,采用GRADE分级评估证据质量。
- 证据质量低至极低;原文未报告其他局限性。
对床旁实践的改变
- 作者认为应每日撤离镇静和神经肌肉阻滞剂以评估神经系统,并监测凝血。
- 证据质量低至极低,作者指出需要更高质量的研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: We determine the frequency, risk factors, and mortality of neurologic complications in adults on extracorporeal membrane oxygenation and propose an algorithm for preventive strategies.
DATA SOURCES: PubMed, Embase, and Cochrane databases.
STUDY SELECTION: Screening was performed using predefined search terms to identify cohort studies reporting neurologic complications in adults during extracorporeal membrane oxygenation from 1990 to 2017.
DATA EXTRACTION: The final reference list was generated on the basis of relevance to the discussed topics. Quality of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation classification of evidence scheme.
DATA SYNTHESIS: In 44 studies, the median frequency of acute neurologic complications is 13% (1-78%; 5% intracranial hemorrhages, 5% ischemic strokes, 2% seizures). Neurologic complications are reported more frequently with venoarterial extracorporeal membrane oxygenation compared with venovenous extracorporeal membrane oxygenation (14 vs eight studies) with a median proportion of complications of 15% (6-33%; 95% CI, 8-19) for venoarterial extracorporeal membrane oxygenation. Median in-hospital mortality is higher with neurologic complications (83%; interquartile range, 54-100% vs 42%; interquartile range, 24-55% without neurologic complications; p < 0.001). Median mortality is 96% for hemorrhages, 84% for ischemic strokes 84%, and 40% for seizures. Risk factors are age, preextracorporeal membrane oxygenation cardiac arrest, hypoglycemia, and administration of inotropes. Hemorrhages are associated with female gender, duration of ventilation and extracorporeal membrane oxygenation, decreased serum fibrinogen, heparin, serum creatinine greater than 2.6 mg/dL, hemodialysis, and thrombocytopenia. Increased odds for ischemic stroke is seen with a preextracorporeal membrane oxygenation serum lactate greater than 10 mmol/L. No studies report daily coagulation monitoring and neurologic assessments, and quality of evidence was low to very low.
CONCLUSIONS: Neurologic complications are reported frequently and with high occurrence rate, especially with venoarterial extracorporeal membrane oxygenation, and associated with high mortality calling for daily weaning from sedation and neuromuscular blockers for neurologic assessment and coagulation monitoring. The low quality of evidence indicates the need for higher quality studies in this context.
参考来源
- Sutter R, Tisljar K, Marsch S, et al. Acute Neurologic Complications During Extracorporeal Membrane Oxygenation: A Systematic Review. Crit Care Med. 2018. PMID: 29782356. doi:10.1097/CCM.0000000000003223
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。